Sugi Predict

Sugi Predict / Compounds / SCHEMBL2320439

SCHEMBL2320439

SCHEMBL2320439

CN1CCN(Cc2ccc(B(O)O)cc2)CC1

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.61
▸ MC4R P32245 1/20 0.59
▸ CHKA P35790 6/20 0.57
▸ CA2 P00918 1/20 0.54
▸ NCF1 P14598 1/20 0.54
▸ PRMT6 Q96LA8 1/20 0.54
▸ HDAC6 Q9UBN7 1/20 0.54
▸ ALDH1A1 P00352 1/20 0.51
▸ NPC1 O15118 2/20 0.49
▸ TP53 P04637 2/20 0.49
▸ RAB9A P51151 2/20 0.49
▸ KDM4E B2RXH2 1/20 0.49
▸ HRH3 Q9Y5N1 3/20 0.48
▸ HPGD P15428 1/20 0.48
▸ LPL P06858 1/20 0.47
▸ LIPG Q9Y5X9 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL21747953 0.98 LMNA (0.59) LMNAMC4RCHKACA2NCF1
SCHEMBL16121611 0.94 CHKA (0.69) LMNAMC4RCHKACA2NCF1
SCHEMBL28440571 0.92 LMNA (0.53) LMNAMC4RCHKACA2NCF1
SCHEMBL14934864 0.89 HRH3 (0.53) LMNAMC4RCHKACA2NCF1
SCHEMBL3716741 0.88 LMNA (0.47) LMNAMC4RCHKACA2NCF1
SCHEMBL29951850 0.86 LPL (0.50) LMNAMC4RCHKACA2ALDH1A1
SCHEMBL27934011 0.86 ALDH1A1 (0.62) LMNACA2ALDH1A1NPC1TP53
SCHEMBL21550770 0.84 PKM (0.54) LMNAMC4RALDH1A1NPC1TP53
SCHEMBL2557827 0.83 HRH3 (0.65) NCF1HDAC6ALDH1A1KDM4EHRH3
SCHEMBL1427526 0.81 HRH3 (0.69) NCF1ALDH1A1KDM4EHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026102563-A1 DISUBSTITUTED PYRIMIDOPYRROLE ANALOG AND USE THEREOF 深圳湾实验室坪山生物医药研发转化中心 2026-05-21 — — WO disclosed
US-12378224-B2 Heteroaryl compounds and their use as Mer inhibitors DONG-A SOCIO HOLDINGS CO., LTD. (KR) 2025-08-05 — — US disclosed
US-20250170138-A1 ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS Epizyme, Inc. 2025-05-29 — — US disclosed
US-12195446-B2 Heteroaryl compounds and their use as therapeutic drugs DONG-A SOCIO HOLDINGS CO., LTD. (KR) 2025-01-14 — — US disclosed
US-12168015-B2 Aryl-or heteroaryl-substituted benzene compounds Epizyme, Inc. (US) 2024-12-17 — — US disclosed
US-12168016-B2 Aryl-OR heteroaryl-substituted benzene compounds Epizyme, Inc. (US) 2024-12-17 — — US disclosed
US-12161645-B2 Aryl-or heteroaryl-substituted benzene compounds Epizyme, Inc. (US) 2024-12-10 — — US disclosed
US-20240277723-A1 ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS Epizyme, Inc. 2024-08-22 — — US disclosed
US-20240245697-A1 ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS Epizyme, Inc. 2024-07-25 — — US disclosed
US-20240245698-A1 ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS Epizyme, Inc. 2024-07-25 — — US disclosed
EP-2231642-A1 PYRIMIDINES AS KINASE INHIBITORS Novartis AG (CH) 2010-09-29 — — EP disclosed
WO-2010055304-A2 PHARMACEUTICAL COMPOUNDS SAREUM LIMITED (GB) 2010-05-20 — — WO disclosed
WO-2010055304-A2 PHARMACEUTICAL COMPOUNDS SAREUM LIMITED (GB) 2010-05-20 — — WO disclosed
EP-2170849-A1 OXAZOLE TYROSINE KINASE INHIBITORS Sareum Limited (GB) 2010-04-07 — — EP disclosed
US-20090215776-A1 Organic compounds ADCOCK CLAIRE 2009-08-27 — — US disclosed
US-20090181941-A1 Pyrrolopyrimidines and Pyrrolopyridines NOVARTIS AG (CH) 2009-07-16 — — US disclosed
WO-2009087225-A2 PYRROLOPYRIMIDINES AND PYRROLOPYRIDINES NOVARTIS AG (CH) 2009-07-16 — — WO disclosed
WO-2009087224-A1 PYRIMIDINES AS KINASE INHIBITORS NOVARTIS AG (CH) 2009-07-16 — — WO disclosed
WO-2008139161-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2008-11-20 — — WO disclosed
WO-2008139161-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2008-11-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12168016-B2 Aryl-OR heteroaryl-substituted benzene compounds AHR, ARNT, CYP1B1 LMNA 2405/4885MC4R 1856/4885CHKA 2056/4885
US-20240245698-A1 ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS AHR, ARNT, CYP1B1 LMNA 2405/4885MC4R 1856/4885CHKA 2056/4885
US-20240277723-A1 ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS AHR, ARNT, CYP1B1 LMNA 2405/4885MC4R 1856/4885CHKA 2056/4885
US-12378224-B2 Heteroaryl compounds and their use as Mer inhibitors MERTK, RET, ERBB2 LMNA 1144/4885MC4R 180/4885CHKA 1780/4885
US-12195446-B2 Heteroaryl compounds and their use as therapeutic drugs MERTK, ERBB2, SRC LMNA 3611/4885MC4R 509/4885CHKA 677/4885
US-20090215776-A1 Organic compounds REN, RXFP1, MYLK LMNA 903/4885MC4R 1915/4885CHKA 3579/4885
US-12161645-B2 Aryl-or heteroaryl-substituted benzene compounds AHR, ARNT, CYP1B1 LMNA 2405/4885MC4R 1856/4885CHKA 2056/4885
US-20250170138-A1 ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS AHR, ARNT, CYP1B1 LMNA 2405/4885MC4R 1856/4885CHKA 2056/4885
US-20240245697-A1 ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS AHR, ARNT, CYP1B1 LMNA 2405/4885MC4R 1856/4885CHKA 2056/4885
US-20090181941-A1 Pyrrolopyrimidines and Pyrrolopyridines ALK, ACVR1, PTPN4 LMNA 2708/4885MC4R 303/4885CHKA 3977/4885
US-12168015-B2 Aryl-or heteroaryl-substituted benzene compounds AHR, ARNT, CYP1B1 LMNA 2405/4885MC4R 1856/4885CHKA 2056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.